- Home
- ACRS vs HOFT Comparison
ACRS vs HOFT Comparison
Compare ACRS & HOFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- HOFT
- Stock Information
- Founded
- ACRS 2012
- HOFT 1924
- Country
- ACRS United States
- HOFT United States
- Employees
- ACRS N/A
- HOFT N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- HOFT Home Furnishings
- Sector
- ACRS Health Care
- HOFT Consumer Discretionary
- Exchange
- ACRS Nasdaq
- HOFT Nasdaq
- Market Cap
- ACRS 137.5M
- HOFT 104.6M
- IPO Year
- ACRS 2015
- HOFT 1999
- Fundamental
- Price
- ACRS $1.46
- HOFT $9.82
- Analyst Decision
- ACRS Strong Buy
- HOFT
- Analyst Count
- ACRS 8
- HOFT 0
- Target Price
- ACRS $9.71
- HOFT N/A
- AVG Volume (30 Days)
- ACRS 709.4K
- HOFT 48.7K
- Earning Date
- ACRS 05-08-2025
- HOFT 06-12-2025
- Dividend Yield
- ACRS N/A
- HOFT 9.37%
- EPS Growth
- ACRS N/A
- HOFT N/A
- EPS
- ACRS N/A
- HOFT N/A
- Revenue
- ACRS $17,777,000.00
- HOFT $397,465,000.00
- Revenue This Year
- ACRS N/A
- HOFT $3.58
- Revenue Next Year
- ACRS $14.59
- HOFT $7.66
- P/E Ratio
- ACRS N/A
- HOFT N/A
- Revenue Growth
- ACRS N/A
- HOFT N/A
- 52 Week Low
- ACRS $0.99
- HOFT $7.34
- 52 Week High
- ACRS $5.17
- HOFT $19.79
- Technical
- Relative Strength Index (RSI)
- ACRS 61.33
- HOFT 55.02
- Support Level
- ACRS $1.22
- HOFT $8.98
- Resistance Level
- ACRS $1.56
- HOFT $9.74
- Average True Range (ATR)
- ACRS 0.09
- HOFT 0.43
- MACD
- ACRS 0.03
- HOFT 0.04
- Stochastic Oscillator
- ACRS 75.00
- HOFT 54.66
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About HOFT Hooker Furnishings Corporation
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.